Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
PHISOHEX is a topical emulsion approved in 1949 for HIV infection and staphylococcal skin infections. The mechanism of action and specific pharmacologic class are not publicly detailed, but the topical route and emulsion formulation suggest direct antimicrobial activity at the skin surface. This is a legacy small-molecule product with limited modern clinical use given advances in systemic HIV therapy.
As LOE approaches, the brand team is likely operating in maintenance/decline mode with minimal staffing expansion; opportunities focus on cost management and transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PHISOHEX offers minimal career growth opportunity; roles are defensive and focused on managing a declining legacy asset. Career professionals should expect limited mobility, flat compensation structures, and transition planning as the product approaches loss of exclusivity and eventual discontinuation.
Worked on PHISOHEX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.